| Full Name | Kentucky Care 112 |
|---|---|
| Speciality | Clinic/Center |
| Location | 120 N 4th St, Barlow, Kentucky |
| Authorized Official Name and Position | Steven F Collier (CEO) |
| Authorized Official Contact | 8703472534 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Kentucky Care 112 Po Box 497 Augusta AR 72006-0497 Ph: (570) 347-2534 | Kentucky Care 112 120 N 4th St Barlow KY 42024-9579 Ph: (270) 334-3131 |
| NPI Number | 1215318019 |
|---|---|
| Provider Enumeration Date | 06/17/2015 |
| Last Update Date | 06/09/2022 |
| Medicare PECOS PAC ID | 2567370620 |
|---|---|
| Medicare Enrollment ID | O20150821012631 |
News Archive
Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Valeant Canada Limited, has received notice that the New Drug Submission for Sublinox has been approved from the Canadian regulatory authority Health Canada.
New statistics released as part of the British Heart Foundation's DECHOX campaign show the true extent of "cake culture" in the office, as around half of people working in Professional Services (48%) who are trying to watch their waistlines say they've ditched the diet at least once after being tempted by sweet treats in the workplace.
A research team led by scientists at the Scripps Translational Science Institute has used whole genome sequencing to identify a new genetic cause of a severe, rare and complex form of epilepsy that becomes evident in early childhood and can lead to early death.
Now, a new study published on the preprint server medRxiv in July 2020 reports that an older treatment modality, namely, the use of convalescent antibody-rich plasma, brings down the mortality rate in hospitalized COVID-19 patients by an astonishing 57%. This adds evidence for the use of convalescent plasma in the treatment of high-risk patients.
Sorrento Therapeutics, Inc. announced today that it has completed its acquisition of Concortis Biosystems, Corp., providing Sorrento with a comprehensive technology platform to create a new generation of homogenous antibody drug conjugates with site-specific toxin conjugation and consistent drug-antibody ratios. With the close of the deal, Sorrento has issued an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders. Based on the closing share price on December 18, 2013, the transaction is valued at $11.3 million.
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215318019 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QF0400X | Clinic/center - Federally Qualified Health Center (fqhc) | (* (Not Available)) | Primary |
News Archive
Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Valeant Canada Limited, has received notice that the New Drug Submission for Sublinox has been approved from the Canadian regulatory authority Health Canada.
New statistics released as part of the British Heart Foundation's DECHOX campaign show the true extent of "cake culture" in the office, as around half of people working in Professional Services (48%) who are trying to watch their waistlines say they've ditched the diet at least once after being tempted by sweet treats in the workplace.
A research team led by scientists at the Scripps Translational Science Institute has used whole genome sequencing to identify a new genetic cause of a severe, rare and complex form of epilepsy that becomes evident in early childhood and can lead to early death.
Now, a new study published on the preprint server medRxiv in July 2020 reports that an older treatment modality, namely, the use of convalescent antibody-rich plasma, brings down the mortality rate in hospitalized COVID-19 patients by an astonishing 57%. This adds evidence for the use of convalescent plasma in the treatment of high-risk patients.
Sorrento Therapeutics, Inc. announced today that it has completed its acquisition of Concortis Biosystems, Corp., providing Sorrento with a comprehensive technology platform to create a new generation of homogenous antibody drug conjugates with site-specific toxin conjugation and consistent drug-antibody ratios. With the close of the deal, Sorrento has issued an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders. Based on the closing share price on December 18, 2013, the transaction is valued at $11.3 million.
› Verified 3 days ago
Ballard County Medical Center, Psc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 120 South 4th Street, Barlow, KY 42024 Phone: 270-534-8999 Fax: 270-534-1670 | |
Ballard County Medical Center Psc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 120 S 4th St, Barlow, KY 42024 Phone: 270-534-8999 Fax: 270-534-1670 |